<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1517-4522</journal-id>
<journal-title><![CDATA[Sociologias]]></journal-title>
<abbrev-journal-title><![CDATA[Sociologias]]></abbrev-journal-title>
<issn>1517-4522</issn>
<publisher>
<publisher-name><![CDATA[Programa de Pós-Graduação em Sociologia - UFRGS]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1517-45222019000100116</article-id>
<article-id pub-id-type="doi">10.1590/15174522-02105004</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Shaping stem cell therapies in Argentina: regulation, risk management and innovation policies]]></article-title>
<article-title xml:lang="es"><![CDATA[La construcción de terapias con células madre en Argentina. Regulación, gestión del riesgo y políticas de innovación]]></article-title>
<article-title xml:lang="pt"><![CDATA[Construção das terapias com células-tronco na Argentina: regulação, gestão de riscos e políticas de inovação]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bortz]]></surname>
<given-names><![CDATA[Gabriela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rosemann]]></surname>
<given-names><![CDATA[Achim]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vasen]]></surname>
<given-names><![CDATA[Federico]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Quilmes Consejo Nacional de Investigaciones Científicas y Técnicas ]]></institution>
<addr-line><![CDATA[Buenos Aires ]]></addr-line>
<country>Argentina</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,University of Exeter  ]]></institution>
<addr-line><![CDATA[Exeter ]]></addr-line>
<country>United Kingdom</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Buenos Aires Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) ]]></institution>
<addr-line><![CDATA[Buenos Aires ]]></addr-line>
<country>Argentina</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<volume>21</volume>
<numero>50</numero>
<fpage>116</fpage>
<lpage>155</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S1517-45222019000100116&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.br/scielo.php?script=sci_abstract&amp;pid=S1517-45222019000100116&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.br/scielo.php?script=sci_pdf&amp;pid=S1517-45222019000100116&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract This paper aims to analyze innovation pathways for stem cell technology in Argentina. Firstly, we present a theoretical perspective on the co-construction of regulation and technology development, positing four main tensions that underlie regulatory building and the shaping of national strategies for regenerative medicine. Regulation is understood as a negotiated process among interests, values, benefits, rewards, and different understandings of safety, efficacy, access and availability. The framework is useful to explore how actors and their visions of desired futures shape the creation of standards and, in turn, how they configure the way these emerging technologies are produced, accessed and used. Secondly, we discuss in detail the Argentine case. We focus on (a) the deployment of state actions on capacity and regulatory building, (b) the creation of new businesses in response to patient expectations, particularly umbilical cord stem cell banks and the supply of experimental treatments, and (c) state-led actions to build a specific regulatory framework (still in the making). Ambiguities and gaps in the current legislation as well as scarce enforcement capabilities configure a legal &#8220;grey area&#8221; for for-profit experimental treatments. Building a specific regulatory framework is understood to be a part of Science, Technology and Innovation (STI) state agencies&#8217; struggle to govern technology development in terms of national envisaged innovation strategies. Lastly, we show how STI authorities and scientists managed to align a broad coalition of actors that encourage international harmonization strategies, following the pharmaceutical model of drug evaluation based on the multi-phase trial system.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Este artículo tiene como objetivo analizar las trayectorias de innovación en terapias con células madre en Argentina. En primer lugar, presentamos una perspectiva teórica sobre la co-construcción de la regulación y del desarrollo tecnológico, y planteamos cuatro tensiones principales que subyacen a la construcción regulatoria y a la conformación de estrategias nacionales para la medicina regenerativa. La regulación es entendida como un proceso de negociación entre intereses, valores, premios, beneficios y diferentes comprensiones sobre las nociones de seguridad, eficacia, acceso y disponibilidad. El marco conceptual es útil para explorar cómo los actores y sus visiones sobre futuros deseados moldean la creación de normativas y, a su vez, cómo éstas configuran la forma en que estas tecnologías emergentes se producen, se utilizan y cómo se accede a ellas. En segundo lugar, discutimos en detalle el caso argentino. Nos centramos en (a) el despliegue de acciones estatales para la construcción de capacidades científicas e institucionales, (b) la creación de nuevos negocios en respuesta a las expectativas de los pacientes, en particular bancos para la preservación de células madre de cordón umbilical y el suministro de tratamientos experimentales, y (c) las iniciativas impulsadas por el Estado para construir un marco regulatorio específico (aún en proceso). Las ambigüedades y los vacíos en la legislación actual, así como las escasas capacidades de aplicación, configuran un &#8220;zona gris&#8221; para los tratamientos experimentales con fines de lucro. La construcción de un marco regulatorio específico es entendida como parte de la búsqueda de las agencias estatales de Ciencia, Tecnología e Innovación (CTI) de gobernar el desarrollo tecnológico en términos de estrategias nacionales de innovación deseadas. Por último, mostramos cómo las autoridades de CTI y científicos lograron alinear una amplia coalición de actores que fomentan estrategias internacionales de armonización, siguiendo el modelo farmacéutico de evaluación de medicamentos basada en el sistema de ensayos clínicos multifase.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo Este artigo visa analisar as vias de inovação da tecnologia de células-tronco na Argentina. Primeiramente, apresentamos um panorama teórico sobre a construção concomitante da regulação e do desenvolvimento tecnológico, postulando quatro principais tensões subjacentes à construção regulatória e à formulação de estratégias nacionais para a medicina regenerativa. A regulação é entendida como um processo negociado entre interesses, valores, benefícios, recompensas e diferentes entendimentos sobre segurança, eficácia, acesso e disponibilidade. O quadro é útil para explorar de que forma os atores e suas visões de futuros desejados definem os padrões e, por sua vez, como estes configuram as formas de produção, acesso e uso dessas tecnologias emergentes. Em segundo lugar, discutimos em detalhes o caso argentino. Nosso foco está (a) na mobilização de ações estatais para desenvolvimento de capacidades e construção regulatória, (b) na criação de novos negócios em resposta às expectativas dos pacientes, particularmente bancos de células-tronco de cordão umbilical e oferta de tratamentos experimentais, e (c) nas iniciativas governamentais de construção de um marco regulatório específico (ainda em formação). Ambiguidades e lacunas na legislação atual bem como a pouca capacidade de imposição da lei configuram uma zona jurídica &#8220;cinzenta&#8221; para tratamentos experimentais com fins lucrativos. Entende-se a construção de um marco regulatório específico como parte da luta dos órgãos estatais de Ciência, Tecnologia e Inovação (CTI) para regular o desenvolvimento tecnológico em termos das estratégias nacionais de inovação concebidas. Por fim, mostramos como as autoridades e cientistas de CTI conseguiram organizar uma ampla coalizão de atores em torno de estratégias de harmonização internacional, seguindo o modelo farmacêutico de avaliação de medicamentos baseada no sistema de testes multifásicos.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Stem cells]]></kwd>
<kwd lng="en"><![CDATA[Regenerative medicine]]></kwd>
<kwd lng="en"><![CDATA[Science Technology and Innovation Policies]]></kwd>
<kwd lng="en"><![CDATA[Regulation]]></kwd>
<kwd lng="en"><![CDATA[Technology governance]]></kwd>
<kwd lng="es"><![CDATA[Células madre]]></kwd>
<kwd lng="es"><![CDATA[Medicina regenerativa]]></kwd>
<kwd lng="es"><![CDATA[Políticas de ciencia]]></kwd>
<kwd lng="es"><![CDATA[tecnología e innovación]]></kwd>
<kwd lng="es"><![CDATA[Regulación]]></kwd>
<kwd lng="es"><![CDATA[Gobernanza tecnológica]]></kwd>
<kwd lng="pt"><![CDATA[Células-tronco]]></kwd>
<kwd lng="pt"><![CDATA[Medicina regenerativa]]></kwd>
<kwd lng="pt"><![CDATA[Políticas de ciência, tecnologia e inovação]]></kwd>
<kwd lng="pt"><![CDATA[Regulação]]></kwd>
<kwd lng="pt"><![CDATA[Governança tecnológica]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[AKRICH]]></surname>
<given-names><![CDATA[Madeleine]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The de-scription of technical objects]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[BIJKER]]></surname>
<given-names><![CDATA[Wiebe]]></given-names>
</name>
<name>
<surname><![CDATA[LAW]]></surname>
<given-names><![CDATA[John]]></given-names>
</name>
</person-group>
<source><![CDATA[Shaping technology/building society. Studies in Sociotechnical Change]]></source>
<year>1992</year>
<page-range>205-24</page-range><publisher-loc><![CDATA[Cambridge ]]></publisher-loc>
<publisher-name><![CDATA[MIT Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ANASTASIA]]></surname>
<given-names><![CDATA[Luigi]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine]]></article-title>
<source><![CDATA[Cell Death &amp; Differentiation]]></source>
<year>2010</year>
<volume>17</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1230-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ARZUAGA]]></surname>
<given-names><![CDATA[Fabiana]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cuestiones éticas y normativas de las investigaciones y terapias con células madre]]></article-title>
<source><![CDATA[Perspectivas Bioéticas]]></source>
<year>2014</year>
<volume>19</volume>
<numero>35-36</numero>
<issue>35-36</issue>
<page-range>79-88</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ARZUAGA]]></surname>
<given-names><![CDATA[Fabiana]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stem cell research and therapies in Argentina: the legal and regulatory approach]]></article-title>
<source><![CDATA[Stem Cells Development]]></source>
<year>2013</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>40-3</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BIN ABDUL AZIZ]]></surname>
<given-names><![CDATA[M. Firdaus]]></given-names>
</name>
<name>
<surname><![CDATA[MORRISON]]></surname>
<given-names><![CDATA[Michael]]></given-names>
</name>
<name>
<surname><![CDATA[KAYE]]></surname>
<given-names><![CDATA[Jane]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Regulating human stem cell research and therapy in low- and middle-income countries: Malaysian perspectives]]></article-title>
<source><![CDATA[New Genetics and Society]]></source>
<year>2017</year>
<volume>37</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>2-20</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BORTZ]]></surname>
<given-names><![CDATA[Gabriela]]></given-names>
</name>
</person-group>
<source><![CDATA[Biotecnologías para el desarrollo inclusivo y sustentable. Políticas públicas y estrategias de producción de conocimiento, desarrollo tecnológico e innovación para resolver problemas sociales y ambientales en Argentina (2007-2016)]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Argentina ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Buenos Aires]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BORTZ]]></surname>
<given-names><![CDATA[Gabriela]]></given-names>
</name>
<name>
<surname><![CDATA[VASEN]]></surname>
<given-names><![CDATA[Federico]]></given-names>
</name>
<name>
<surname><![CDATA[ROSEMANN]]></surname>
<given-names><![CDATA[Achim]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Entre oportunidad y riesgo: regulación, expectativas y políticas CTI para células madre en Argentina]]></article-title>
<source><![CDATA[Ciencia, Docencia y Tecnología]]></source>
<year>2017</year>
<volume>28</volume>
<numero>54</numero>
<issue>54</issue>
<page-range>38-74</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BRAITHWAITE]]></surname>
<given-names><![CDATA[John]]></given-names>
</name>
<name>
<surname><![CDATA[COGLIANESE]]></surname>
<given-names><![CDATA[Cary]]></given-names>
</name>
<name>
<surname><![CDATA[LEVI-FAUR]]></surname>
<given-names><![CDATA[David]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Can regulation and governance make a difference?]]></article-title>
<source><![CDATA[Regulation &amp; Governance]]></source>
<year>2007</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CALLON]]></surname>
<given-names><![CDATA[Michel]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The dynamics of techno-economic networks]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[COOMBS]]></surname>
<given-names><![CDATA[Rod]]></given-names>
</name>
<name>
<surname><![CDATA[SAVIOTTI]]></surname>
<given-names><![CDATA[Paolo]]></given-names>
</name>
<name>
<surname><![CDATA[WALSH]]></surname>
<given-names><![CDATA[Vivien]]></given-names>
</name>
</person-group>
<source><![CDATA[Technological change and company strategies]]></source>
<year>1992</year>
<page-range>72-102</page-range><publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Harcourt Brace Jovanovich]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[CÉLULAS MADRE: BUSCAN REGULARLAS como remedios biológicos y frenar el vacío legal en el país]]></article-title>
<source><![CDATA[Clarín]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="">
<collab>COMISIÓN ASESORA EN TERAPIAS CELULARES Y MEDICINA REGENERATIVA</collab>
<source><![CDATA[Investigación y células madre: nociones para un debate necesario]]></source>
<year>2009</year>
<month>a</month>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="">
<collab>COMISIÓN ASESORA EN TERAPIAS CELULARES Y MEDICINA REGENERATIVA</collab>
<source><![CDATA[Declaración acerca de la guarda de células madre de sangre de cordón umbilical]]></source>
<year>2009</year>
<month>b</month>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="">
<collab>COMISIÓN ASESORA EN TERAPIAS CELULARES Y MEDICINA REGENERATIVA</collab>
<source><![CDATA[Claves para el debate sobre células madre]]></source>
<year>2009</year>
<month>c</month>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="">
<collab>COMISIÓN ASESORA EN TERAPIAS CELULARES Y MEDICINA REGENERATIVA</collab>
<source><![CDATA[Células madre: sólo existen dos tratamientos clínicamente aprobados]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<collab>CONICET</collab>
<article-title xml:lang=""><![CDATA[Células madre: &#8220;Van a ser una revolución en medicina&#8221;]]></article-title>
<source><![CDATA[CONICET]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DE SANTO]]></surname>
<given-names><![CDATA[Yésica]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pacientes se unieron para alertar sobre las estafas con células madre]]></article-title>
<source><![CDATA[Tiempo Argentino]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="">
<collab>FEDERACIÓN ARGENTINA DE ENFERMEDADES POCO FRECUENTES</collab>
<source><![CDATA[Florencia Braga Menéndez: presentation at Stem Cell Summit 2013]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="">
<collab>FEDERACIÓN ARGENTINA DE ENFERMEDADES POCO FRECUENTES</collab>
<source><![CDATA[Informe sobre ensayo clínico con células madres en pacientes con lesiones oculares]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[FERRERAS]]></surname>
<given-names><![CDATA[Andrés]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Células madres: China ofrece en Córdoba los tratamientos]]></article-title>
<source><![CDATA[La Voz]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[FUROR SOLIDARIO en las redes sociales por Helenita]]></article-title>
<source><![CDATA[Clarín]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GARAU]]></surname>
<given-names><![CDATA[Joaquín]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cuánto cuesta guardar células madre en la Argentina]]></article-title>
<source><![CDATA[Revista Apertura]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GOTTWEIS]]></surname>
<given-names><![CDATA[Herbert]]></given-names>
</name>
<name>
<surname><![CDATA[MINGER]]></surname>
<given-names><![CDATA[Stephen]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[iPS cells and the politics of promise]]></article-title>
<source><![CDATA[Nature Biotechnology]]></source>
<year>2008</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>271-2</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GOTTWEIS]]></surname>
<given-names><![CDATA[Herbert]]></given-names>
</name>
<name>
<surname><![CDATA[PRAINSACK]]></surname>
<given-names><![CDATA[Barbara]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emotion in political discourse: contrasting approaches to stem cell governance in the USA, UK, Israel and Germany]]></article-title>
<source><![CDATA[Regenerative Medicine]]></source>
<year>2006</year>
<volume>1</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>823-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GREENWOOD]]></surname>
<given-names><![CDATA[Heather]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Regenerative medicine and the developing world]]></article-title>
<source><![CDATA[PLoS Medicine]]></source>
<year>2006</year>
<volume>3</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GRIPPO]]></surname>
<given-names><![CDATA[Andrés]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Células madre para curar la desesperanza]]></article-title>
<source><![CDATA[Materia]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[GUARDAR CÉLULAS MADRE no es egoísmo sino protección biológica para hijos y familia]]></article-title>
<source><![CDATA[Clarín]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HARMON]]></surname>
<given-names><![CDATA[Shawn]]></given-names>
</name>
<name>
<surname><![CDATA[KALE]]></surname>
<given-names><![CDATA[Dinar]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Regulating in developing countries: Multiple roles for medical research and products regulation in Argentina and India]]></article-title>
<source><![CDATA[Technology in Society]]></source>
<year>2015</year>
<volume>43</volume>
<page-range>10-22</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HARTMAN]]></surname>
<given-names><![CDATA[Irene]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Células madre: un futuro clínico prometedor entre estafas y promesas engañosas]]></article-title>
<source><![CDATA[Clarín]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[JASANOFF]]></surname>
<given-names><![CDATA[Sheila]]></given-names>
</name>
<name>
<surname><![CDATA[KIM]]></surname>
<given-names><![CDATA[Sang-Hyun]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Containing the atom: sociotechnical imaginaries and nuclear power in the United States and South Korea]]></article-title>
<source><![CDATA[Minerva]]></source>
<year>2009</year>
<volume>47</volume>
<page-range>119-46</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KRMPOTIC]]></surname>
<given-names><![CDATA[Claudia]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Creer en la cura. Eficacia simbólica y control social en las prácticas del Dr. M.]]></article-title>
<source><![CDATA[Scripta Ethnologica]]></source>
<year>2011</year>
<volume>XXXIII</volume>
<page-range>97-116</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[LAS PREPAGAS también deben costear los tratamientos con células madre]]></article-title>
<source><![CDATA[Diario Judicial]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LASCOUMES]]></surname>
<given-names><![CDATA[Pierre]]></given-names>
</name>
<name>
<surname><![CDATA[LE GALES]]></surname>
<given-names><![CDATA[Patrick]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Introduction: Understanding public policy through its instruments. From the nature of instruments to the sociology of public policy Instrumentation]]></article-title>
<source><![CDATA[Governance]]></source>
<year>2007</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-21</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[LEVÁNTENSE Y ANDEN]]></article-title>
<source><![CDATA[Página 12]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LUNA]]></surname>
<given-names><![CDATA[Florencia]]></given-names>
</name>
<name>
<surname><![CDATA[SALLES]]></surname>
<given-names><![CDATA[Arleen]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Investigación con células madre: el debate ético]]></article-title>
<source><![CDATA[Perspectivas Bioéticas]]></source>
<year>2014</year>
<volume>19</volume>
<numero>35-36</numero>
<issue>35-36</issue>
<page-range>47-52</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MATTIS]]></surname>
<given-names><![CDATA[Virginia]]></given-names>
</name>
<name>
<surname><![CDATA[SVENDSEN]]></surname>
<given-names><![CDATA[Clive]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Induced pluripotent stem cells: a new revolution for clinical neurology?]]></article-title>
<source><![CDATA[The Lancet Neurology]]></source>
<year>2011</year>
<volume>10</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>383-94</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MCMAHON]]></surname>
<given-names><![CDATA[Dominique]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The global industry for unproven stem cell interventions and stem cell tourism]]></article-title>
<source><![CDATA[Tissue Engineering and Regenerative Medicine]]></source>
<year>2014</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MCMAHON]]></surname>
<given-names><![CDATA[Dominique]]></given-names>
</name>
<name>
<surname><![CDATA[THORSTEINSDÓTTIR]]></surname>
<given-names><![CDATA[Halla]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pursuing endogenous high-tech innovation in developing countries: a look at regenerative medicine innovation in Brazil, China and India]]></article-title>
<source><![CDATA[Research Policy]]></source>
<year>2013</year>
<volume>42</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>965-74</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MIKAMI]]></surname>
<given-names><![CDATA[Koichi]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[State-supported science and imaginary lock-in: the case of regenerative medicine in Japan]]></article-title>
<source><![CDATA[Science as Culture]]></source>
<year>2015</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>183-204</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="">
<collab>MINISTERIO DE CIENCIA, TECNOLOGÍA E INNOVACIÓN PRODUCTIVA</collab>
<source><![CDATA[Se realizó la 2da conferencia internacional sobre células madre]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="book">
<collab>MINISTERIO DE CIENCIA, TECNOLOGÍA E INNOVACIÓN PRODUCTIVA</collab>
<source><![CDATA[Plan nacional de ciencia, tecnología e innovación 2012-2015]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Buenos Aires ]]></publisher-loc>
<publisher-name><![CDATA[MCTIP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="book">
<collab>MINISTERIO DE CIENCIA, TECNOLOGÍA E INNOVACIÓN PRODUCTIVA</collab>
<source><![CDATA[Plan nacional de ciencia, tecnología e innovación &#8220;Argentina inovadora 2020&#8221;]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Buenos Aires ]]></publisher-loc>
<publisher-name><![CDATA[MCTIP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="">
<collab>MINISTERIO DE CIENCIA, TECNOLOGÍA E INNOVACIÓN PRODUCTIVA</collab>
<source><![CDATA[Crece el debate sobre las terapias avanzadas en la Argentina]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PALMA]]></surname>
<given-names><![CDATA[Verónica]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stem cell research in Latin America: update, challenges and opportunities in a priority research area]]></article-title>
<source><![CDATA[Regenerative Medicine]]></source>
<year>2015</year>
<volume>10</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>785-98</page-range></nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PÉREZ]]></surname>
<given-names><![CDATA[Carlota]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Technological change and opportunities for development as a moving target]]></article-title>
<source><![CDATA[Cepal Review]]></source>
<year>2001</year>
<volume>75</volume>
<page-range>109-30</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PITOSSI]]></surname>
<given-names><![CDATA[Fernando]]></given-names>
</name>
<name>
<surname><![CDATA[PODHAJCER]]></surname>
<given-names><![CDATA[Osvaldo]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current status of stem cells and regenerative medicine research in Argentina]]></article-title>
<source><![CDATA[Stem Cells and Development]]></source>
<year>2014</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>17-9</page-range></nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="book">
<collab>RED DE INDICADORES DE CIENCIA Y TECNOLOGÍA</collab>
<source><![CDATA[El estado de la ciencia]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Buenos Aires ]]></publisher-loc>
<publisher-name><![CDATA[RICYT]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<collab>RESEARCH AND MARKETS</collab>
<article-title xml:lang=""><![CDATA[Global Stem Cells Market Research Report 2018]]></article-title>
<source><![CDATA[Markets Insider]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ROSEMANN]]></surname>
<given-names><![CDATA[Achim]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global regulatory developments for clinical stem cell research: diversification and challenges to collaborations]]></article-title>
<source><![CDATA[Regenerative Medicine]]></source>
<year>2016</year>
<volume>11</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>647-57</page-range></nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ROSEMANN]]></surname>
<given-names><![CDATA[Achim]]></given-names>
</name>
<name>
<surname><![CDATA[BORTZ]]></surname>
<given-names><![CDATA[Gabriela]]></given-names>
</name>
<name>
<surname><![CDATA[VASEN]]></surname>
<given-names><![CDATA[Federico]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Regulatory developments for nonhematopoietic stem cell therapeutics: perspectives from the EU, the USA, Japan, China, India, Argentina, and Brazil]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[CHEN]]></surname>
<given-names><![CDATA[Xiao-Dong]]></given-names>
</name>
</person-group>
<source><![CDATA[A roadmap to non-hematopoietic stem cell-based therapeutics. From the bench to the clinic]]></source>
<year>2018</year>
<page-range>463-92</page-range><publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ROSEMANN]]></surname>
<given-names><![CDATA[Achim]]></given-names>
</name>
<name>
<surname><![CDATA[VASEN]]></surname>
<given-names><![CDATA[Federico]]></given-names>
</name>
<name>
<surname><![CDATA[BORTZ]]></surname>
<given-names><![CDATA[Gabriela]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global diversification in medicine regulation: insights from regenerative stem cell medicine]]></article-title>
<source><![CDATA[Science as Culture]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ROSEMANN]]></surname>
<given-names><![CDATA[Achim]]></given-names>
</name>
<name>
<surname><![CDATA[CHAISINTHOP]]></surname>
<given-names><![CDATA[Nattaka]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The pluralization of the international: resistance and alter-standardization in regenerative stem cell medicine]]></article-title>
<source><![CDATA[Social Studies of Science]]></source>
<year>2016</year>
<volume>46</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>112-39</page-range></nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SABATIER]]></surname>
<given-names><![CDATA[Paul]]></given-names>
</name>
<name>
<surname><![CDATA[WEIBLE]]></surname>
<given-names><![CDATA[Christopher]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The advocacy coalition framework]]></article-title>
<source><![CDATA[Theories of the policy process]]></source>
<year>2007</year>
<volume>2</volume>
<page-range>189-220</page-range></nlm-citation>
</ref>
<ref id="B53">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SALTER]]></surname>
<given-names><![CDATA[Brian]]></given-names>
</name>
<name>
<surname><![CDATA[ZHOU]]></surname>
<given-names><![CDATA[Yinhua]]></given-names>
</name>
<name>
<surname><![CDATA[DATTA]]></surname>
<given-names><![CDATA[Saheli]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hegemony in the marketplace of biomedical innovation: consumer demand and stem cell science]]></article-title>
<source><![CDATA[Soc Sci Med]]></source>
<year>2015</year>
<volume>131</volume>
<page-range>156-63</page-range></nlm-citation>
</ref>
<ref id="B54">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SALTER]]></surname>
<given-names><![CDATA[Brian]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Governing stem cell science in China and India: emerging economies and the global politics of innovation]]></article-title>
<source><![CDATA[New Genetics and Society]]></source>
<year>2008</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>145-59</page-range></nlm-citation>
</ref>
<ref id="B55">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SINGER]]></surname>
<given-names><![CDATA[Emily]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A stem-cell revolution]]></article-title>
<source><![CDATA[MIT Technology Review]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B56">
<nlm-citation citation-type="">
<source><![CDATA[SISTEMA DE INFORMACIÓN DE CIENCIA Y TECNOLOGÍA ARGENTINO (SICYTAR)]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B57">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SLEEBOOM-FAULKNER]]></surname>
<given-names><![CDATA[Margaret]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparing national home-keeping and the regulation of translational stem cell applications: an international perspective]]></article-title>
<source><![CDATA[Social Science &amp; Medicine]]></source>
<year>2016</year>
<volume>153</volume>
<page-range>240-9</page-range></nlm-citation>
</ref>
<ref id="B58">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SLEEBOOM-FAULKNER]]></surname>
<given-names><![CDATA[Margaret]]></given-names>
</name>
<name>
<surname><![CDATA[PATRA]]></surname>
<given-names><![CDATA[Prasanna K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The bioethical vacuum: national policies on human embryonic stem cell research in India and China]]></article-title>
<source><![CDATA[Journal of International Biotechnology Law]]></source>
<year>2008</year>
<volume>5</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>221-34</page-range></nlm-citation>
</ref>
<ref id="B59">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[STEKOLSCHIK]]></surname>
<given-names><![CDATA[Gabriel]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Las madres de la ilusión]]></article-title>
<source><![CDATA[Revista EXACTAmente]]></source>
<year>2008</year>
<volume>14</volume>
<numero>39</numero>
<issue>39</issue>
</nlm-citation>
</ref>
<ref id="B60">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[THERBORN]]></surname>
<given-names><![CDATA[Göran]]></given-names>
</name>
</person-group>
<source><![CDATA[La ideología del poder y el poder de la ideología]]></source>
<year>1989</year>
<publisher-loc><![CDATA[Mexico ]]></publisher-loc>
<publisher-name><![CDATA[Siglo XXI]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B61">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[THOMAS]]></surname>
<given-names><![CDATA[Hernan]]></given-names>
</name>
<name>
<surname><![CDATA[BECERRA]]></surname>
<given-names><![CDATA[Lucas]]></given-names>
</name>
<name>
<surname><![CDATA[GARRIDO]]></surname>
<given-names><![CDATA[Santiago]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Socio-technical dynamics of counter-hegemony and resistance]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[GODIN]]></surname>
<given-names><![CDATA[Benoit]]></given-names>
</name>
<name>
<surname><![CDATA[VINCK]]></surname>
<given-names><![CDATA[Dominique]]></given-names>
</name>
</person-group>
<source><![CDATA[Critical studies of innovation: alternative approaches to the pro-innovation bias]]></source>
<year>2017</year>
<page-range>182-200</page-range><publisher-loc><![CDATA[Edward Elgar ]]></publisher-loc>
<publisher-name><![CDATA[UK-US]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B62">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[VASEN]]></surname>
<given-names><![CDATA[Federico]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Regulación tecnológica y valores sociales: un análisis del caso farmacéutico]]></article-title>
<source><![CDATA[Scientiae Studia]]></source>
<year>2008</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>409-26</page-range></nlm-citation>
</ref>
<ref id="B63">
<nlm-citation citation-type="">
<collab>VISION GAIN</collab>
<source><![CDATA[Global stem cell technologies and applications market 2018-2028]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B64">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WEBSTER]]></surname>
<given-names><![CDATA[Andrew]]></given-names>
</name>
<name>
<surname><![CDATA[HADDAD]]></surname>
<given-names><![CDATA[Christian]]></given-names>
</name>
<name>
<surname><![CDATA[WALDBY]]></surname>
<given-names><![CDATA[Catherine]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Experimental heterogeneity and standardisation: stem cell products and the clinical trial process]]></article-title>
<source><![CDATA[BioSocieties]]></source>
<year>2011</year>
<volume>6</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>401-19</page-range></nlm-citation>
</ref>
<ref id="B65">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ZWANENBERG]]></surname>
<given-names><![CDATA[Patrick van]]></given-names>
</name>
<name>
<surname><![CDATA[ELY]]></surname>
<given-names><![CDATA[Adrian]]></given-names>
</name>
<name>
<surname><![CDATA[SMITH]]></surname>
<given-names><![CDATA[Adrian]]></given-names>
</name>
</person-group>
<source><![CDATA[Regulating technology: international harmonization and local realities]]></source>
<year>2011</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Routledge]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
